cabozantinib,atezolizumab
roche
['cabo ', 'contact-03', 'atezo']
#kidneycancer contact-03 shows no significant improvement in pfs or os w cabo/atezo vs cabo in post-pd1 setting. presentation by at #asco23. orr also very similar. hard to find a group that seemed to benefit/warrant further study for atezo in this setting. 
Med onc at UW/SCCA/Fred Hutch focused on melanoma and RCC, interested in patient/caregiver QOL and all things immunotherapy. All opinions are my own.